Company intelligence / Profile preview
Aspargo Laboratories
- Ownership
- Private
- Development stage
- NDA
Overview
Aspargo Labs has developed a proprietary oral suspension formulation of sildenafil citrate (ASP‑001), achieving regulatory approval and commercial launch under the brand names HEZKUE® in Germany and BANDOL® in Spain. The product has also received approval in the UK, Mexico, Ireland, and the Netherlands. Clinical trials have been completed to support an NDA submission to the FDA. Top-line results from bioavailability studies show comparable absorption to Viagra®, with ongoing expansion into new geographies and additional products under development.
- Therapeutic areas
- OtherMen's Health
- Modalities
- Oral suspensions (liquid formulations)Oral spraysSmall molecules (notably sildenafil citrate)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Aspargo Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aspargo Laboratories.